Study S001437

A Comparator-Controlled Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control (HbA1c) and Safety in Asian Subjects With Type 2 Diabetes Mellitus Managed With Oral Antidiabetic Medications

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00917267
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 691
Start: 2009-07
Primary completion: 2010-09
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:exenatide once weekly; DRUG:exenatide twice daily
Results posted: TRUE

Registered primary outcomes

Change in HbA1c From Baseline to Week 26. [Baseline, Week 26]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026430	Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. Onishi Y, Journal of diabetes investigation	2013	Randomized trial	PMID 24843650 DOI	cites ClinicalTrials.gov:NCT00917267; registry reference DERIVED:24843650
R0026895	Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. Ji L, Journal of diabetes investigation	2013	Randomized trial	PMID 24843631 DOI	cites ClinicalTrials.gov:NCT00917267; registry reference DERIVED:24843631